Expect significant downward pressure on VRAX as the market absorbs the 548,000 new shares at $6 and accounts for the massive warrant overhang (Series A and B for up to 1.64M additional shares). Monitor for shareholder approval of authorized share increase, which could trigger further dilution if warrants are exercised.
Price Chart
Executive Summary
Virax Biolabs is raising $3.3M through exercise of preferred investment options at a reduced price of $6/share, while issuing new warrants for up to 1.64M additional shares. The gross proceeds exceed the company's entire $3M market cap, indicating massive dilution that is highly bearish for existing shareholders.
Key Financial Metrics
Key Facts
- Gross proceeds of approximately $3.3 million from exercise of 548,000 ordinary shares at $6.00 per share
- Original exercise price was reduced from $10.00 to $6.00 per share
- New Series A Warrants issued for up to 548,000 shares and Series B Warrants for up to 1,096,000 shares, each at $6.00 exercise price
- Offering proceeds exceed the company's $3 million market capitalization
- Expected to close on or about July 10, 2026; H.C. Wainwright acting as placement agent
- Proceeds to be used for working capital and general corporate purposes
Financial Impact
Dilutive capital raise of $3.3M (110% of market cap) with additional warrant overhang of up to 1.64M shares
Risk Factors
- Extreme dilution relative to current market capitalization
- Additional dilution from Series A and B warrants if exercised
- Possible failure to obtain shareholder approval for authorized share increase, creating execution risk
- No revenue or earnings disclosed to offset the dilutive impact
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-prn-302822153 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 16d ago | 6-K | $1.85 | awaiting T+20 | — | $1.24 (−32.97%) |
Sep 4, 2026 7w ago | 6-K | $2.63 $2.03 | ▲ +22.81% | ▲ +24.53% | $1.24 (+52.85%) |
Sep 4, 2026 7w ago | EFFECT | $2.63 $2.40 | ▼ −8.57% | ▼ −9.17% | $1.24 (−52.76%) |
Aug 18, 2026 9w ago | 6-K | $2.76 $2.45 | ▼ −11.20% | ▼ −10.21% | $1.24 (−55.07%) |
Jul 31, 2026 12w ago | 6-K | $2.62 $2.82 | ▼ −7.63% | ▼ −4.65% | $1.24 (+52.67%) |
Jul 16, 2026 14w ago | 6-K | $3.90 $2.82 | ▼ −27.69% | ▼ −31.31% | $1.24 (−68.21%) |
Jul 9, 2026 15w ago | Press Release | $6.36 $2.77 | ▲ +56.45% | ▲ +58.69% | $1.24 (+80.50%) |
Jul 9, 2026 15w ago | 6-K | $6.36 $2.77 | ▼ −56.45% | ▼ −58.69% | $1.24 (−80.50%) |
Jun 24, 2026 17w ago | 6-K | $0.1350 $0.1276 | ▼ −5.48% | ▼ −6.11% | $1.24 (+818.52%) |
Jun 12, 2026 19w ago | 6-K | $0.1840 $0.1496 | ▼ −18.70% | ▼ −20.05% | $1.24 (+573.91%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers